-
- Discover what goes into a successful AAV formulation strategy
- Learn which formulation factors drive potency and stability
- See real-world case studies showing the impact of smart formulation design
About our speakers
Kelly Walsh, Senior Scientist I
Kelly Walsh is a drug product development scientist with over a decade of experience in biologics and advanced therapies. She’s currently a senior scientist at OXB, where she supports downstream and drug product development for AAV and Lentivirus. Her background includes complex formulation development, container closure selection, fill-finish process development, and clinical administration design across multiple modalities. With a strong foundation in CMC, Kelly brings a practical, science-driven approach to developing drug products that are stable, scalable, and ready for the clinic.
Eugenia Fandunyan, Associate Director Analytical Development
Eugenia Fandunyan is a biotech scientist with 9 years’ experience in analytical development within the cell and gene therapy industry. She’s currently the Associate Director of Analytical Development at OXB, where she leads a team focused on developing and optimizing bioassays for AAV and lentiviral vectors. Her expertise are vast, covering everything from gene expression to functional potency, in support of release and stability testing. Eugenia has a background in both GMP and early-phase work, and she’s passionate about building robust, phase-appropriate methods that actually make it to the clinic.